Yosprala combines aspirin, an antiplatelet, and omeprazole, a proton pump inhibitor.
The authors found that compared to the use of H2RA therapy, patients initiated on PPI therapy had a 25% increased risk of death (hazard ratio [HR] 1.25, 95% CI: 1.23-1.28).
In patients with Barrett's esophagus, use of proton pump inhibitors (PPIs) did not lead to dysplasia- or cancer-protective effects.
Takeda announced that the Food and Drug Administration (FDA) has approved Dexilant (dexlansoprazole) delayed-release capsules and Dexilant SoluTab delayed-release orally-disintegrating tablets for patients aged 12-17 years with gastroesophageal reflux disease (GERD).
IDWEEK 2016 - Adult Infectious Diseases
Use of proton pump inhibitors (PPIs) was tied to a higher risk of infectious gastroenteritis hospitalization with increasing risk among increasing doses.
Use of proton pump inhibitors (PPIs) increase the risk of an adult experiencing a heart attack by 16 to 21 percent compared to those who don't use commonly prescribed antacids, a large study has found.
Limited research published in Annals of Pharmacotherapy suggests that use of proton pump inhibitors (PPI) is associated with myopathy-like symptoms without long-term effects after discontinuation.
Dr. Reddy's Laboratories announced the launch of Esomeprazole Magnesium Delayed-Release Capsules, the generic version of AstraZeneca's Nexium Delayed-Release Capsules.
Long-term use of proton pump inhibitors (PPIs) reduces bleeding-related mortality in patients with cirrhosis and variceal bleeding, a prospective study reported at The Liver Meeting® 2016.
The Food and Drug Administration (FDA) has approved Ivax Pharmaceutical's Esomeprazole Magnesium Delayed-Release Capsules, the first generic version of AstraZeneca's Nexium.